Form 4: BioCryst Pharmaceuticals Director Receives Stock Options and Restricted Stock Units

Machelle Sanders, a director at BioCryst Pharmaceuticals, received stock options and restricted stock units as part of the company's Non-Employee Director Compensation Policy.

Summary

• On June 12, 2024, Machelle Sanders, a director at BioCryst Pharmaceuticals, received an automatic grant of 49,933 stock options with an exercise price of $6.30.
• These options vest on June 12, 2025, and expire on June 12, 2034.
• Sanders also received 6,820 restricted stock units (RSUs) that will vest on the first anniversary of the grant date.
• Following these transactions, Sanders directly owns 32,431 shares of BioCryst Pharmaceuticals stock and 49,933 stock options.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Director compensation through stock options and RSUs is a common practice in the pharmaceutical industry to incentivize performance and align the interests of directors with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across the pharmaceutical industry.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options and restricted stock units as part of their director compensation packages.
• The size of the grant is comparable to grants made by similar-sized pharmaceutical companies.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants positively as they align the director's interests with the company's long-term success.

Key Dates